Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.55 |
| ▸ | HPGD | P15428 | 5/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.55 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | HSD11B1 | P28845 | 7/20 | 0.50 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.50 |
| ▸ | GLA | P06280 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | CTPS1 | P17812 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16827647 | 0.80 | SCN9A (0.50) | SCN9ACTPS1 | |
| SCHEMBL29464233 | 0.80 | SCN9A (0.50) | SCN9ACTPS1 | |
| SCHEMBL24369034 | 0.80 | SCN9A (0.50) | SCN9ACTPS1 | |
| SCHEMBL29826535 | 0.80 | SCN9A (0.50) | SCN9ACTPS1 | |
| SCHEMBL18725653 | 0.80 | SCN9A (0.50) | SCN9ACTPS1 | |
| SCHEMBL12017942 | 0.77 | ALDH1A1 (0.64) | ALDH1A1KDM4EHPGDHSD17B10LMNA | |
| SCHEMBL17868449 | 0.76 | KDM4E (0.50) | KDM4ELMNASCN9ACTPS1 | |
| SCHEMBL24369035 | 0.76 | CTPS1 (0.55) | SCN9ACTPS1 | |
| SCHEMBL24369036 | 0.76 | CTSK (0.52) | HSD11B1SCN9ACTPS1 | |
| SCHEMBL17803526 | 0.74 | CTPS1 (0.42) | ALDH1A1KDM4EHPGDL3MBTL1HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9777030-B2 | Complexes | JOHNSON MATTHEY PUBLIC LIMITED COMPANY (GB) | 2017-10-03 | — | — | US | disclosed |
| US-20170120231-A1 | COMPLEXES | JOHNSON MATTHEY PUBLIC LIMITED COMPANY (GB) | 2017-05-04 | — | — | US | disclosed |
| US-20170120231-A1 | COMPLEXES | JOHNSON MATTHEY PUBLIC LIMITED COMPANY (GB) | 2017-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170120231-A1 | COMPLEXES | AP3M1, CYCS, AP1M1 | ALDH1A1 1792/4885KDM4E 4105/4885HPGD 1920/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.